Yamagishi Sho-ichi
Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine.
Nihon Rinsho. 2010 May;68(5):809-13.
Recent clinical studies have substantiated the concept of 'metabolic memory' in the pathogenesis of cardiovascular disease (CVD) in diabetes. Indeed, DCCT-EDIC Research, has revealed that intensive therapy during the DCCT reduces the risk of cardiovascular events by about 50% in type 1 diabetic patients 11 years after the end of the trial. Among various biochemical pathways activated under diabetic conditions, the process of formation and accumulation of advanced glycation end products (AGEs) and their mode of action are most compatible with the theory of 'metabolic memory'. Further, there is a growing body of evidence that AGEs and their receptor RAGE interaction plays an important role in CVD in diabetes. These observations suggest that the blockade of AGE-RAGE system may be a promising therapeutic target for CVD in diabetes. In this paper, we review the role of the AGE-RAGE axis in diabetic macroangiopathy.
近期的临床研究证实了糖尿病心血管疾病（CVD）发病机制中“代谢记忆”的概念。事实上，糖尿病控制与并发症试验后续研究（DCCT-EDIC研究）表明，在糖尿病控制与并发症试验期间进行强化治疗，可使1型糖尿病患者在试验结束11年后发生心血管事件的风险降低约50%。在糖尿病条件下激活的各种生化途径中，晚期糖基化终末产物（AGEs）的形成和积累过程及其作用方式与“代谢记忆”理论最为相符。此外，越来越多的证据表明，AGEs与其受体RAGE的相互作用在糖尿病患者的心血管疾病中起重要作用。这些观察结果表明，阻断AGE-RAGE系统可能是糖尿病心血管疾病的一个有前景的治疗靶点。在本文中，我们综述了AGE-RAGE轴在糖尿病大血管病变中的作用。
